Overview
Minimal change disease (MCD) is a common cause of nephrotic syndrome, characterized by podocyte foot process fusion without significant histological changes visible under light microscopy 1.Diagnosis
Primary Indication: Nephrotic syndrome (proteinuria, hypoalbuminemia, hyperlipidemia, edema) 1.
Diagnostic Test: Renal biopsy essential for definitive diagnosis, showing characteristic podocyte changes 1.
Laboratory Findings: Elevated serum creatinine (median 0.7 mg/dL), normal to mildly reduced eGFR (mean 104 ± 33 ml/min/1.73 m2) 1.
Age Consideration: Chronic histopathological changes more prevalent in patients over 40 years 1.Management
First-Line Treatment: Corticosteroids (e.g., prednisone) are the mainstay of treatment 1.
Adjunctive Therapy: In cases of steroid resistance or frequent relapses, consider calcineurin inhibitors (e.g., cyclosporine, tacrolimus) 1.
Monitoring: Regular follow-up to assess renal function and response to therapy 1.Special Populations
Pediatrics: MCD can occur in children, sometimes associated with unusual conditions like partial lipodystrophy 3.
Elderly: Older patients may exhibit more chronic histopathological changes, warranting closer monitoring 1.Key Recommendations
Renal biopsy is essential for confirming the diagnosis of minimal change disease in patients presenting with nephrotic syndrome (Evidence: Strong 1).
Corticosteroids should be initiated as first-line therapy for managing nephrotic syndrome due to MCD (Evidence: Strong 1).
Patients aged 40 years and older with MCD should be monitored closely for chronic histopathological changes, potentially impacting renal prognosis (Evidence: Moderate 1).References
1 Aydin Z, Yilmaz M, Sipahioglu M, Dervisoglu E, Aydemir N, Uzun S et al.. Demographic, clinical and laboratory characteristics of adult-onset minimal change disease in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group. International urology and nephrology 2023. link
2 Cheung PK, Stulp B, Immenschuh S, Borghuis T, Baller JF, Bakker WW. Is 100KF an isoform of hemopexin? Immunochemical characterization of the vasoactive plasma factor 100KF. Journal of the American Society of Nephrology : JASN 1999. link
3 Jacob CK, Date A, Shastry JC. Minimal change disease with partial lipodystrophy. Child nephrology and urology 1988. link